Classical markers like ER and Ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: Results from the GEICAM/2002-01 phase II study

1. Sánchez-Rovira, P.
2. Antón, A.
3. Barnadas, A.
4. Velasco, A.
5. Lomas, M.
6. Rodríguez-Pinilla, M.
7. Ramírez, J.L.
8. Ramírez, C.
9. Ríos, M.J.
10. Castellá, E.
11. García-Andrade, C.
12. San Antonio, B.
13. Carrasco, E.
14. Palacios, J.L.